STTR Phase I: Compact Aberration Compensated Focus and Scan Control for Biomedical Sensors

STTR 第一阶段：生物医学传感器的紧凑型像差补偿聚焦和扫描控制

• 批准号: 0810778
• 负责人: Brant Kaylor
• 金额: --
• 依托单位: Bridger Photonics, INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-07-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0810778&HistoricalAwards=false
• 关键词: STTR; Phase; Compact; Aberration; Compensated

This Small Business Technology Transfer Phase I project will demonstrate the technical and commercial feasibility of an innovative aberration compensated focus control device for a revolutionary improvement in medical imaging. Currently, a variety of medical conditions are diagnosed and treated through in vitro imaging of suspicious tissues, requiring invasive, time-consuming biopsies. Several in vivo medical imaging technologies have been developed and shown to be efficacious for disease diagnosis and treatment (confocal, OCT, etc.). These commercial systems, however, remain too large for imaging of most native biological systems. This is due to the size of the optical assemblies, the manner in which they are raster scanned to create images, and inherent optical aberrations induced during scanning. This project will solve these problems by creating a compact, miniaturized aberration free focus control/scanning device by combining two critical innovations: extremely small, low cost, large stroke, micro-electro-mechanical deformable mirrors for focus control and compensation of spherical aberration and a miniaturized wavefront sensor to detect and control aberrations induced by the deformable mirror. After providing critical proof-of-concept demonstrations, the team will create a prototype device design and determine its technical feasibility based upon its expected performance and projected size, weight and power consumption. The potential commercial payoff for this miniaturized aberration compensated focus control/raster scanning device is very large. Applications encompass not only biomedical imaging but extend to other markets including digital cameras and cell phone cameras. Conservative market estimates suggest that within the next three years, sales of this device could provide gross annual revenues greater than $27M. The team will consult with industry experts, engage potential customers for the medical imaging market, and identify market insertion points for the device. The team will also contact major cell phone and digital camera manufacturers. Based upon the response from these potential customers, the examination of the competitive landscape, and the projected time to market, the team will determine the device's commercial feasibility.

这个小型企业转移阶段I项目将证明创新畸变补偿焦点控制设备的技术和商业可行性，以革命性的医学成像改进。当前，通过对可疑组织的体外成像进行诊断和治疗多种医疗状况，需要侵入性，耗时的活检。已经开发了几种体内医学成像技术，并证明对疾病诊断和治疗有效（共焦，OCT等）。但是，这些商业系统对于大多数天然生物系统的成像仍然太大。这是由于光学组件的大小，即它们被扫描以创建图像的方式以及在扫描过程中诱导的固有的光差。该项目将通过结合两个关键创新来创建紧凑，微型畸变的无重点控制/扫描设备来解决这些问题：极其小，低成本，大笔画，微型机械机械可变形的镜子，以用于焦点控制和赔偿球形畸变的焦点控制，并通过可识别和控制型号的微型波形传感器来检测和控制差异。在提供了关键的概念验证演示之后，团队将创建原型设备设计，并根据其预期性能以及预计的尺寸，重量和功耗确定其技术可行性。这种微型畸变补偿焦点控制/栅格扫描设备的潜在商业收益非常大。应用不仅包括生物医学成像，而且还涉及到其他市场，包括数码相机和手机摄像机。保守的市场估计表明，在未来三年内，该设备的销售额可能会提供超过2700万美元的年收入。该团队将咨询行业专家，吸引潜在客户进入医疗成像市场，并确定该设备的市场插入点。该团队还将联系主要的手机和数码相机制造商。根据这些潜在客户的反应，竞争格局的检查以及预计的市场时间，该团队将确定设备的商业可行性。